section name header

Pronunciation

meth-ill-FEN-i-date

Indications

REMS

Oral, orally distintegrating tablets, and transdermal:

Oral only:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Slow and incomplete after oral administration; absorption of sustained or extended-release tablet (SR) is delayed and provides continuous release; well absorbed from skin. Aptensio XR, Metadate CD, Concerta, Ritalin LA — provides initial rapid release followed by a second continuous release (biphasic release).

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized (80%) by the liver.

Half-life: 2–4 hr.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: SUDDEN DEATH, hypertension, palpitations, tachycardia, hypotension, peripheral vasculopathy.

Derm: contact sensitization (erythema, edema, papules, vesicles) (transdermal), erythema, loss of skin pigmentation (transdermal), rash.

EENT: blurred vision, teeth grinding.

GI: anorexia, constipation, cramps, diarrhea, dry mouth, metallic taste, nausea, vomiting.

GU: priapism.

Metab: growth suppression (especially with prolonged use), weight loss (especially with prolonged use).

MS: RHABDOMYOLYSIS.

Neuro: akathisia, dyskinesia, tics , hyperactivity, insomnia, restlessness, tremor, behavioral disturbances, dizziness, hallucinations, headache, irritability, mania, thought disorder.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA), fever, physical dependence, psychological dependence, tolerance.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

Attention-Deficit/Hyperactivity Disorder

Narcolepsy

Implementation

US Brand Names

Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT, Jornay PM, Metadate CD, Methylin, Methylin ER, Quillichew ER, Quillivant XR, Ritalin, Ritalin LA

methylphenidate (Transdermal): Daytrana

Canadian Brand Names

Biphentin, Foquest, Ritalin SR

Contr. Subst. Schedule

Schedule II (C-II)

Classifications

Therapeutic Classification: central nervous system stimulants

Availability

(Generic available)

Time/Action Profile

(CNS stimulation)

ROUTEONSETPEAKDURATION
POunknown1–3 hr4–6 hr
PO-ERunknown4–7 hr3–12 hr
Transdermalunknownunknown12 hr

†Depends on formulation.

Assessment

Lab Test Considerations:

Patient/Family Teaching

Evaluation/Desired Outcomes

Code

NDC Code*